Elevation Oncology, Inc. (ELEV): Price and Financial Metrics
ELEV Price/Volume Stats
| Current price | $0.48 | 52-week high | $5.89 |
| Prev. close | $0.51 | 52-week low | $0.36 |
| Day low | $0.48 | Volume | 101,357 |
| Day high | $0.50 | Avg. volume | 778,982 |
| 50-day MA | $0.55 | Dividend yield | N/A |
| 200-day MA | $1.50 | Market Cap | 20.44M |
ELEV Stock Price Chart Interactive Chart >
Elevation Oncology, Inc. (ELEV) Company Bio
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
Latest ELEV News From Around the Web
Below are the latest news stories about ELEVATION ONCOLOGY INC that investors may wish to consider to help them evaluate ELEV as an investment opportunity.
Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare ConferenceElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 8:30 am ET. |
Elevation Oncology Inc (ELEV) Reports Q3 2023 Financial ResultsCompany's Cash Position Strengthens, R&D and G&A Expenses Decrease |
Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business AchievementsElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the third quarter ended September 30, 2023, and highlighted recent business achievements. |
Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra, Chief Executive Officer of Elevation Oncology, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 12:00 pm ET. |
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal |
ELEV Price Returns
| 1-mo | 7.84% |
| 3-mo | -36.93% |
| 6-mo | -83.33% |
| 1-year | -47.51% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -49.47% |
| 2022 | -84.22% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...